You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company said it delivered 4,480 DecisionDx-Melanoma test reports in Q4 2019 compared to 3,270 reports in Q4 2018.
The San Diego-based company plans to develop a flexible, modular, and high-performing sequencing platform based on proprietary technologies in different areas.
A genome-wide association meta-analysis involving almost one million heart failure cases and controls identified 11 risk loci and helped distinguish potential causal contributors.
The clinical study will evaluate a next-generation sequencing-based test, which has the potential to detect all known respiratory pathogens in 12 hours.
The San Diego firm has now raised at least $145 million to drive development of its DNA sequencing platform and build manufacturing and commercial operations.
The deal follows a number of recent acquisitions in the animal genomics space for Neogen including Canadian animal genomics firm Delta Genomics Centre.
The additional funds follow the $25 million that the company announced in May 2019, bringing the total figure for the round to $45 million.
The multi-center registry study aims to measure the clinical impact of serial testing with Signatera in patients with stage II or stage III colorectal cancer.
The investigators used gene expression, chromatin interaction, and functional annotations to prioritize 191 genes as targets of potentially causal variants.
The magistrate did recommend that the court dismiss two counts made against Natera with respect to trademark disparagement and unfair trade practices.
Researchers discovered a duplication affecting the RYR2 gene in two families, which may indicate that it is a founder mutation in the Amish population.
Some of these shared loci were associated with higher BMI, but some were linked to lower BMI, particularly those also linked to schizophrenia.
The Durham, North Carolina-based startup will use the funds to develop a library preparation kit for single-cell sequencing.
In a large group of participants followed for decades, baseline body mass index outperformed a SNP-based obesity risk score for predicting midlife weight.
The firm said its panel, which runs on its MDx-3000 system, tests nasopharyngeal swabs for the most common viruses and bacteria.
The new guidelines are meant to assist medical professionals in understanding the complexity and implications of exome sequencing in prenatal care.
The partners will focus on optimizing technology and conducting clinical utility studies for liquid biopsy and tissue-based genomic applications.
Mayo Clinic Ventures and NTT Venture Capital have invested in the AI software developer to synthesize biomedical data for drug development and precision medicine.
Veracyte will provide Acerta Pharma, a division of AstraZeneca, with genomic information to support its development of oncology therapeutics.
Palmetto has expanded coverage of the ClonoSeq assay to include monitoring MRD testing for patients with chronic lymphocytic leukemia (CLL.)
The funding supports development of a low-cost platform for detection of antimicrobial resistance elements in complex microbial communities.
The partners are studying wild-type cardiac amyloidosis, a rare condition characterized by the accumulation of abnormal proteins in the heart.
NEB plans to expand its product lines into new areas of research including genome editing, the companies said.
The University of Washington spinout will use the funding to commercialize duplex sequencing technology to detect low-frequency DNA mutations.
A genome-wide association study involving some 200,000 veterans unearthed five anxiety risk loci in European Americans and another risk locus in African Americans.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.